PhRMA Reports 450 Medicines in Development for Rare Diseases - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PhRMA Reports 450 Medicines in Development for Rare Diseases



The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that biopharmaceutical research companies are developing 452 new medicines for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders. According to FDA, in the last five years, one third of all new drug approvals were for rare diseases.

The 452 medicines and vaccines in development for rare diseases, all in human clinical trials or under review by FDA, include 105 for cancer, 85 for genetic disorders, 65 for blood cancers, and 32 for neurological disorders.

Source: Pharmaceutical Research and Manufacturers of America

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here